Educational only — not medical advice, not a diagnosis. This page describes what users commonly discuss with their licensed healthcare provider around this topic. We do not diagnose, treat, cure, reverse, or fix any condition. No compound listed is recommended. Work with a licensed clinician for any decision.
Home/Conditions/Elevated Visceral Fat
METABOLIC — EDUCATIONAL GUIDE

Elevated Visceral Fat

The metabolically-active abdominal fat linked to cardiovascular + insulin-resistance risk. Hard to see; visible in labs.

What This Is

Visceral adipose tissue (VAT) is the fat stored around the organs inside the abdominal cavity — distinct from subcutaneous fat (under the skin). It's metabolically active and drives systemic inflammation, insulin resistance, and cardiovascular risk. Unlike total body fat, visceral fat can be high even in people who look relatively lean.

Direct measurement options include DEXA scan (body composition) and abdominal MRI. Proxy measures include waist circumference (>40" men / >35" women suggests elevation) and waist-to-hip ratio. Lab markers don't measure VAT directly but reflect its metabolic consequences.

Tesamorelin has FDA approval specifically for visceral fat reduction in HIV-associated lipodystrophy and is used off-label by many under clinician supervision for broader visceral-fat work. Lifestyle levers (caloric deficit, resistance training, sleep, stress management) are foundational.

Biomarkers Users Commonly Track

The following lab markers are commonly discussed with a licensed provider in this context. They are not a diagnostic checklist. Only your clinician can interpret what these values mean for your specific situation.

Triglycerides<100 mg/dL · ideal <80 mg/dL fasting
Strongly correlated with visceral fat mass.
Fasting Insulin<10 mIU/L · ideally 2–6 mIU/L for metabolic optimization
Rises with VAT accumulation.
HDL-C50–80 mg/dL — extremely high levels (>90) carry their own concerns
Inversely correlated — drops as VAT rises.
ALT<25 U/L is a common metabolic-optimization target
Hepatic fat (NAFLD) and VAT travel together.
hs-CRP<1.0 mg/L — often <0.5 mg/L in highly optimized individuals
VAT is the primary driver of systemic low-grade inflammation.
HbA1c<5.4% (metabolic optimization target)
Downstream metabolic signal.

Compounds Users Research (Ask Your Clinician)

No compound below is a recommended treatment. These are research-stage or investigational compounds that users commonly look up in this context. Any decision about their use is a conversation with a licensed healthcare provider, under their supervision, with full understanding of risks and your personal history.
Tesamorelin
FDA-approved for visceral fat reduction in HIV-lipodystrophy. Used off-label under clinician supervision for other populations.
aod-9604
GH-fragment studied for lipolytic effect without IGF-1 impact — research-stage in most populations.
Semaglutide
Weight loss with GLP-1s typically reduces visceral fat disproportionately — clinician-supervised.
Tirzepatide
Similar body-composition shift pattern.

Related Reading

Related Conditions

Metabolic SyndromeInsulin ResistanceElevated ApoB (Cardiovascular Risk)
Bring the data to your next visit.

MyProtocolStack lets you log the biomarkers on this page across lab draws, chart the trend, and hand a structured report to your clinician. Better conversations start with better data. We do not replace your provider; we help you show up prepared.

Start tracking free →
Compliance notice: This page is informational and educational only. MyProtocolStack does not provide medical advice, diagnosis, or treatment. All references to biomarkers are educational. All references to compounds describe what users research and typically discuss with their clinician — not endorsements or treatment recommendations. Reference ranges vary by laboratory. Symptom interpretation and any protocol decisions require a licensed healthcare provider. If you are experiencing symptoms, consult your clinician.